Name | 2,4-Dichloro-5-methoxyaniline |
Synonyms | 4,6-Dichloro-m-anisidine 5-AMINO-4,6-DICHLOROANISOLE 2,4-Dichloro-5-methoxyaniline 2,4-DICHLORO-5-METHOXYANILINE 2,4-dichloro-5-methoxy aniline 2,4-Dichloro-5-methoxyphenylamine 2,4-Dichloro-5-methoxybenzenamine 2,4-dichloro-5-methoxyphenylamine 2,4-dichloro-5-methoxy-Benzenamine BENZENAMINE,2,4-DICHLORO-5-METHOXY- 5-Amino-2,4-dichloroanisole, 4,6-Dichloro-m-anisidine 5-Amino-2,4-dichloroanisole, 4,5-Dichloro-m-anisidine |
CAS | 98446-49-2 |
EINECS | 619-345-9 |
InChI | InChI=1/C7H7Cl2NO/c1-11-7-3-6(10)4(8)2-5(7)9/h2-3H,10H2,1H3 |
InChIKey | AJROJTARXSATEB-UHFFFAOYSA-N |
Molecular Formula | C7H7Cl2NO |
Molar Mass | 192.04 |
Density | 1.375±0.06 g/cm3(Predicted) |
Melting Point | 51 °C |
Boling Point | 290.1±35.0 °C(Predicted) |
Flash Point | 129.3°C |
Solubility | Chloroform (Slightly), Methanol (Slightly) |
Vapor Presure | 0.00211mmHg at 25°C |
Appearance | Solid |
Color | Pale Brown |
pKa | 1.59±0.10(Predicted) |
Storage Condition | Keep in dark place,Sealed in dry,Room Temperature |
Refractive Index | 1.587 |
MDL | MFCD00974410 |
Risk Codes | R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
UN IDs | UN2810 |
Hazard Note | Irritant |
Hazard Class | 6.1 |
Packing Group | III |
Use | 2, 4-dichloro-5-methoxyaniline is mainly used for the preparation of the intermediate 4-[(2, 4-dichloro-5-methoxyphenyl)] amino] -6-methoxy-7-(3-chloropropoxy)-3-quinolinecarbonitrile. bosutinib, developed by Wyeth Pharmaceuticals, was approved by the European Union in September 2010 as an "orphan drug" for the treatment of chronic myeloid leukemia (CML). On September 4, 2012, the drug was approved by the U. S. Food and Drug Administration (FDA), and the trade name was Bosulif. Approved by European Food and Drug Administration (EMA) on March 27, 2013 and approved by Japanese PMDA on September 26, 2014. |